These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 27525386)

  • 21. Cabozantinib: a review of its use in patients with medullary thyroid cancer.
    Hoy SM
    Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Selpercatinib in
    Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
    N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 24. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
    J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
    Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
    Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
    Miles D; Jumbe NL; Lacy S; Nguyen L
    Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher
    Mulè C; Ciampi R; Ramone T; Prete A; Matrone A; Cappagli V; Torregrossa L; Basolo F; Elisei R; Romei C
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VEGF, VEGFR3, and PDGFRB protein expression is influenced by RAS mutations in medullary thyroid carcinoma.
    Mancikova V; Inglada-Pérez L; Curras-Freixes M; de Cubas AA; Gómez Á; Letón R; Kersten I; Leandro-García LJ; Comino-Méndez I; Apellaniz-Ruiz M; Sánchez L; Cascón A; Sastre-Marcos J; García JF; Rodríguez-Antona C; Robledo M
    Thyroid; 2014 Aug; 24(8):1251-5. PubMed ID: 24754736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
    Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
    Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
    Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI
    Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabozantinib for the treatment of advanced medullary thyroid cancer.
    Nagilla M; Brown RL; Cohen EE
    Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
    Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
    J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
    Hellerstedt BA; Vogelzang NJ; Kluger HM; Yasenchak CA; Aftab DT; Ramies DA; Gordon MS; Lara P
    Clin Lung Cancer; 2019 Mar; 20(2):74-81.e1. PubMed ID: 30528315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 3 Trial of Selpercatinib in Advanced
    Hadoux J; Elisei R; Brose MS; Hoff AO; Robinson BG; Gao M; Jarzab B; Isaev P; Kopeckova K; Wadsley J; Führer D; Keam B; Bardet S; Sherman EJ; Tahara M; Hu MI; Singh R; Lin Y; Soldatenkova V; Wright J; Lin B; Maeda P; Capdevila J; Wirth LJ;
    N Engl J Med; 2023 Nov; 389(20):1851-1861. PubMed ID: 37870969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.